📣 VC round data is live. Check it out!

Ascentage Pharma Group Valuation Multiples

Discover revenue and EBITDA valuation multiples for Ascentage Pharma Group and similar public comparables like Stoke Therapeutics, Cheezheng Tibetan Medicine, Zhejiang Wolwo Bio-Pharma, Sarepta Therapeutics and more.

Ascentage Pharma Group Overview

About Ascentage Pharma Group

Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies. The company's geographical segments include the United States and Mainland China.


Founded

2009

HQ

China

Employees

567

Financials (LTM)

Revenue: $103M
EBITDA: ($153M)

EV

$2B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Ascentage Pharma Group Financials

Ascentage Pharma Group reported last 12-month revenue of $103M and negative EBITDA of ($153M).

In the same LTM period, Ascentage Pharma Group generated $95M in gross profit, ($153M) in EBITDA losses, and had net loss of ($170M).

Revenue (LTM)


Ascentage Pharma Group P&L

In the most recent fiscal year, Ascentage Pharma Group reported revenue of $85M and EBITDA of ($161M).

Ascentage Pharma Group is unprofitable as of last fiscal year, with gross margin of 91%, EBITDA margin of (191%), and net margin of (213%).

See analyst estimates for Ascentage Pharma Group
LTMLast FY202320242025202620272028
Revenue$103M$85M$33M$145M$85M
Gross Profit$95M$77M$28M$140M$77M
Gross Margin92%91%86%97%91%
EBITDA($153M)($161M)($110M)($35M)($161M)
EBITDA Margin(149%)(191%)(335%)(24%)(191%)
EBIT Margin(166%)(209%)(393%)(38%)(209%)
Net Profit($170M)($180M)($136M)($60M)($183M)
Net Margin(165%)(213%)(417%)(41%)(216%)

Financial data powered by Morningstar, Inc.

Ascentage Pharma Group Stock Performance

Ascentage Pharma Group has current market cap of $2B, and enterprise value of $2B.

Market Cap Evolution


Ascentage Pharma Group's stock price is $5.02.

Ascentage Pharma Group share price decreased by 11.9% in the last 30 days, and by 21.6% in the last year.

Ascentage Pharma Group has an EPS (earnings per share) of $-0.48.

See more trading valuation data for Ascentage Pharma Group
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$2B$2B-2.0%-11.9%-16.2%-21.6%$-0.48

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Ascentage Pharma Group Valuation Multiples

Ascentage Pharma Group trades at 17.6x EV/Revenue multiple, and (11.8x) EV/EBITDA.

See NTM and 2027E valuation multiples for Ascentage Pharma Group

EV / Revenue (LTM)


Ascentage Pharma Group Financial Valuation Multiples

As of May 16, 2026, Ascentage Pharma Group has market cap of $2B and EV of $2B.

Ascentage Pharma Group has a P/E ratio of (11.0x).

LTMLast FY202320242025202620272028
EV/Revenue17.6x21.3x55.1x12.5x21.3x
EV/EBITDA(11.8x)(11.2x)(16.4x)(51.4x)(11.2x)
EV/EBIT(10.6x)(10.2x)(14.0x)(33.1x)(10.2x)
EV/Gross Profit19.1x23.3x63.9x12.8x23.3x
P/E(11.0x)(10.4x)(13.7x)(31.3x)(10.2x)
EV/FCF(10.4x)(10.3x)(15.6x)(90.1x)(10.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Ascentage Pharma Group Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Ascentage Pharma Group Margins & Growth Rates

Ascentage Pharma Group grew revenue by 60% but EBITDA decreased by 17% in the last fiscal year.

In the most recent fiscal year, Ascentage Pharma Group reported gross margin of 91%, EBITDA margin of (191%), and net margin of (213%).

See estimated margins and future growth rates for Ascentage Pharma Group

Ascentage Pharma Group Margins

Last FY202420252026202720282029
Gross Margin91%97%91%93%
EBITDA Margin(191%)(24%)(191%)(99%)
EBIT Margin(209%)(38%)(209%)(116%)
Net Margin(213%)(41%)(216%)(112%)
FCF Margin(208%)(14%)(209%)(126%)

Ascentage Pharma Group Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth60%342%(41%)60%
Gross Profit Growth62%397%(45%)62%
EBITDA Growth(17%)(68%)361%(17%)
EBIT Growth(11%)(58%)224%(11%)
Net Profit Growth(16%)(56%)207%(17%)
FCF Growth(3%)(83%)786%(4%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Ascentage Pharma Group Operational KPIs

Ascentage Pharma Group's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.4M for the same period.

Ascentage Pharma Group's Rule of 40 is (39%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Ascentage Pharma Group's Rule of X is 51% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Ascentage Pharma Group
LTMLast FY202320242025202620272028
Rule of 40(87%)(39%)
Bessemer Rule of X5%51%
Revenue per Employee$0.1M
Opex per Employee$0.4M
S&M Expenses to Revenue55%62%88%20%62%
G&A Expenses to Revenue61%78%82%19%43%
R&D Expenses to Revenue146%198%318%97%198%
Opex to Revenue300%479%135%300%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Ascentage Pharma Group Competitors

Ascentage Pharma Group competitors include Stoke Therapeutics, Cheezheng Tibetan Medicine, Zhejiang Wolwo Bio-Pharma, Sarepta Therapeutics, Granules India, Intellia Therapeutics, AnaptysBio, InventisBio, ADMA Biologics and Guobang Pharma.

Most Ascentage Pharma Group public comparables operate across Biopharmaceuticals, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Stoke Therapeutics8.3x12.2x(465.4x)(19.9x)
Cheezheng Tibetan Medicine4.5x11.8x
Zhejiang Wolwo Bio-Pharma10.7x10.2x23.1x
Sarepta Therapeutics1.0x1.1x(3.7x)(12.7x)
Granules India3.5x3.4x15.7x15.3x
Intellia Therapeutics23.8x24.9x(3.9x)(3.9x)
AnaptysBio6.7x8.1x22.6x22.9x
InventisBio297.5x161.0x(36.8x)(36.6x)

This data is available for Pro users. Sign up to see all Ascentage Pharma Group competitors and their valuation data.

Start Free Trial

Ascentage Pharma Group Funding History

Before going public, Ascentage Pharma Group raised $238M in total equity funding, across 3 rounds.


Ascentage Pharma Group Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jul-18Series CArrowMark Partners; CCB International; CTS Capital; HDY International Investment; Oriza Seed Capital (Oriza Yuandian); Teng Yue Partners; YuanMing Capital$150MAscentage Pharma Group is a biopharmaceutical company focused on developing novel small-molecule therapies, particularly targeting apoptosis pathways for cancer and other diseases. The company underwent a reorganization in July 2018, establishing Ascentage Pharma Group International as the holding company. The specified Series C funding round on July 17, 2018, involved investors including YuanMing Capital (lead), ArrowMark Partners, CCB International, CTS Capital, HDY International Investment, Oriza Seed Capital, and Teng Yue Partners. The company has since progressed with products like olverembatinib (commercialized) and lisaftoclax (in preparation). Subsequent developments include a $75M Corporate Minority - P2P round in June 2024, a U.S. IPO in January 2025 raising net proceeds of US$132.5M, and a HK$1,492.5M placing in July 2025. Ascentage continues global clinical trials and commercialization efforts in oncology.
Dec-16Series BOriza Holdings; RMB Funds; SDIC Fund Management; YuanMing Capital$72MAscentage Pharma Group is a biopharmaceutical company focused on research and development, operating through subsidiaries like Ascentage Pharma (Hong Kong, incorporated May 22, 2009) for investment holding and business development. In November 2017, the company acquired shares in Ascentage Pharma from founders for nominal HKD amounts.
Aug-15Series ABioVenture; EFung Capital; Grains Valley Venture Capital; Oriza Seed Capital (Oriza Yuandian); YuanMing Capital$16MAscentage Pharma Group raised $15.5 million in a Series A round co-led by Oriza Seed Capital and YuanMing Capital, with participation from EFung Capital, BioVenture Capital, and Grains Valley Venture Capital. The company, based in Hong Kong with operations in China, focuses on research and development in the biopharmaceutical sector.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Ascentage Pharma Group

When was Ascentage Pharma Group founded?Ascentage Pharma Group was founded in 2009.
Where is Ascentage Pharma Group headquartered?Ascentage Pharma Group is headquartered in China.
How many employees does Ascentage Pharma Group have?As of today, Ascentage Pharma Group has over 567 employees.
Who is the CEO of Ascentage Pharma Group?Ascentage Pharma Group's CEO is Dajun Yang.
Is Ascentage Pharma Group publicly listed?Yes, Ascentage Pharma Group is a public company listed on HKEX.
What is the stock symbol of Ascentage Pharma Group?Ascentage Pharma Group trades under 06855 ticker.
When did Ascentage Pharma Group go public?Ascentage Pharma Group went public in 2019.
Who are competitors of Ascentage Pharma Group?Ascentage Pharma Group main competitors include Stoke Therapeutics, Cheezheng Tibetan Medicine, Zhejiang Wolwo Bio-Pharma, Sarepta Therapeutics, Granules India, Intellia Therapeutics, AnaptysBio, InventisBio, ADMA Biologics, Guobang Pharma.
What is the current market cap of Ascentage Pharma Group?Ascentage Pharma Group's current market cap is $2B.
What is the current revenue of Ascentage Pharma Group?Ascentage Pharma Group's last 12 months revenue is $103M.
What is the current revenue growth of Ascentage Pharma Group?Ascentage Pharma Group revenue growth (NTM/LTM) is 61%.
What is the current EV/Revenue multiple of Ascentage Pharma Group?Current revenue multiple of Ascentage Pharma Group is 17.6x.
Is Ascentage Pharma Group profitable?No, Ascentage Pharma Group is not profitable.
What is the current EBITDA of Ascentage Pharma Group?Ascentage Pharma Group has negative EBITDA and is not profitable.
What is Ascentage Pharma Group's EBITDA margin?Ascentage Pharma Group's last 12 months EBITDA margin is (149%).
What is the current EV/EBITDA multiple of Ascentage Pharma Group?Current EBITDA multiple of Ascentage Pharma Group is (11.8x).
What is the current FCF of Ascentage Pharma Group?Ascentage Pharma Group's last 12 months FCF is ($174M).
What is Ascentage Pharma Group's FCF margin?Ascentage Pharma Group's last 12 months FCF margin is (169%).
What is the current EV/FCF multiple of Ascentage Pharma Group?Current FCF multiple of Ascentage Pharma Group is (10.4x).
How many companies Ascentage Pharma Group has acquired to date?Ascentage Pharma Group hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Ascentage Pharma Group has invested to date?Ascentage Pharma Group hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Ascentage Pharma Group

Lists including Ascentage Pharma Group

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial